DIAGNOSTIC TECHNIQUE FOR STAGES OF HEPATIC FIBROSIS IN PATIENTS WITH CHRONIC VIRAL HEPATITIS Russian patent published in 2015 - IPC A61B8/00 A61B5/107 

FIELD: medicine.

SUBSTANCE: patient's serum asparagine aminotransferase (AST) is measured. That is combined with duplex scanning to measure a splenic vein diameter (SVD) and a body weight. The measured AST, SVD and body weight are used to calculate a fibrosis index by formula: FI=-6.31+0.19*AST-1.02*SVD+0.24*BW, wherein FI is the fibrosis index, -6.31 is a constant, 0.19-1.02 and 0.24 are the coefficients, AST is blood serum asparagine aminotransferase (Unit/l), SVD is the splenic vein diameter (mm), and BW is the patient's body weight (kg). The constant and coefficients in the presented formula are calculated by multiple regression method; a dependent variable is a liver density value according to ultrasonic elastography findings. If the derived fibrosis index is less than 6.3, the absence of fibrosis (stage F0) is stated. If the fibrosis falls within the range of 6.3 to 8.3, the first stage of fibrosis (F1) is diagnosed. The fibrosis index of 8.4 to 10.8 corresponds to the second stage of fibrosis (F2). The fibrosis index of 10.9 to 13.9 corresponds to the third stage of fibrosis (F3). If the fibrosis index is more than 13.9, hepatic cirrhosis (stage F4) is diagnosed.

EFFECT: technique provides the adequate differentiation of the fibrosis stages in the patients with chronic viral hepatitis by the complex assessment of biochemical, ultrasonic and antropometric parameters.

5 ex